Business Wire

Agreena’s Farmer Payout for a Second Harvest Year Demonstrates That Carbon Certificates Help Fund and Expedite Farmers’ Transition to Regenerative Practices

14.6.2023 08:43:00 EEST | Business Wire | Press release

Share

Agtech company Agreena, whose soil carbon platform is the largest in Europe operating in 16 countries and developed to help farmers finance their transition to regenerative practices, today announced the results of its second harvest year (HY) and second annual early payout to participating European farmers. The number of hectares enrolled grew 10X over the previous year and farmer participation increased 4X. Agreena is paying the largest incentives to farmers under a soil carbon scheme to-date at €32 to €36 per anticipated carbon certificate generated depending on region, an increase of up to 45% from last year. The company is a pioneer in creating nature-based soil carbon removals. The associated certificates will soon be available on the market for companies that want to participate in the transition of the world’s farmers to practices that help address climate change, biodiversity loss and the future of food security.

While carbon sequestration in agriculture has been identified as one of the top solutions to scale climate action because of its accessibility and the immediate impact it can have, the primary hurdle to adoption is the high upfront costs for farmers. By leveraging the voluntary carbon market (VCM) to convert climate-friendly farming efforts into high-quality carbon certificates, Agreena is driving a new revenue stream to the farmer. Farmers are seeing the benefit too. Twenty percent of the year-on-year hectare growth in Agreena’s portfolio came from member farmers adding more land to the program.

“Agreena is introducing a new category of carbon certificates into the market and it will take time to build and scale, but farmers cannot wait - they need a reliable and liquid payment to help cover their transition efforts,” said Simon Haldrup, CEO of Agreena. “That is why Agreena takes a calculated risk and pays farmers each harvest year. Still, carbon certificates are just one part of the solution and a mix of incentives is needed to rapidly transition the world’s farmers to regenerative practices.”

Farmers and the companies that rely on carbon certificates for their ESG and sustainability efforts are on different timelines. Sales of credits can take a year or longer to occur after the impact has been certified. Agreena’s early payout option for farmers bridges the gap between the two. Farmers enrolled in Agreena’s program get to decide how they’d like to use the certificates that they generate, and one of those options is to be paid soon after the harvest year ends to help cover their upfront costs. The early payout is based on market prices at the time. Growth of the Voluntary Carbon Market and pricing for high-quality carbon certificates continue to grow, any upside when Agreena’s certificates are sold is shared with the farmer.

Agreena’s carbon certificates are the result of farmers taking measures to sequester additional carbon from the atmosphere within their soils and at the same time reduce their own emissions through practices like no till. The company has developed a highly credible programme that is in alignment with the latest IPCC science and the recognised principles of the VCM, and built relationships with agricultural partners and farmers across Europe.

More recently Agreena has developed its corporate unit that oversees certificate sales, and MRV and risk solutions. Agreena works with certificate buyers to tailor, structure and scale portfolios from across the company’s inventory, modelled after assets already sold and traded in traditional financial markets.

“Our first vintage of high quality carbon certificates originates from farmers in Central Europe and has just been made available for a limited quantity presale,” said Frederik Aagaard, Agreena’s Director of Carbon Markets. “We’re delighted to be able to facilitate the participation of companies in helping finance this journey for farmers.”

The deadline for enrolling in Agreena’s 2023 programme is quickly approaching. Farmers have until June 30 to enter this year’s harvest, and can calculate their earning potential and apply by completing this form on Agreena’s website. More information about the programme and how it works can be found here.

Agreena anticipates that as the VCM continues to grow and evolve, the market will see continued developments related to certification and new standards in the space. Agreena’s portfolio of GHG reduction and carbon removal certificates are accredited to the ISO 14064-2 standard and are currently undergoing Verra VCS certification. The outcome is anticipated before the end of the year.

About Agreena

Agreena unlocks the power of soil carbon removals and natural capital to finance the transition to regenerative agriculture. Working in close collaboration with partner farmers across 16 European markets and growing, AgreenaCarbon is Europe’s leading soil carbon platform. Combined with market-leading satellite monitoring technologies, Agreena’s solutions can support farmers, companies, and governments on the road to net zero.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nicole Shore
Nicole.Shore@agreena.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye